219 related articles for article (PubMed ID: 27310306)
1. Collaboration of MLLT1/ENL, Polycomb and ATM for transcription and genome integrity.
Ui A; Yasui A
Nucleus; 2016 Apr; 7(2):138-45. PubMed ID: 27310306
[TBL] [Abstract][Full Text] [Related]
2. Transcriptional elongation factor ENL phosphorylated by ATM recruits polycomb and switches off transcription for DSB repair.
Ui A; Nagaura Y; Yasui A
Mol Cell; 2015 May; 58(3):468-82. PubMed ID: 25921070
[TBL] [Abstract][Full Text] [Related]
3. Human Polymerase-Associated Factor complex (PAFc) connects the Super Elongation Complex (SEC) to RNA polymerase II on chromatin.
He N; Chan CK; Sobhian B; Chou S; Xue Y; Liu M; Alber T; Benkirane M; Zhou Q
Proc Natl Acad Sci U S A; 2011 Sep; 108(36):E636-45. PubMed ID: 21873227
[TBL] [Abstract][Full Text] [Related]
4. The Intrinsically Disordered Proteins MLLT3 (AF9) and MLLT1 (ENL) - Multimodal Transcriptional Switches With Roles in Normal Hematopoiesis, MLL Fusion Leukemia, and Kidney Cancer.
Kabra A; Bushweller J
J Mol Biol; 2022 Jan; 434(1):167117. PubMed ID: 34174329
[TBL] [Abstract][Full Text] [Related]
5. Cooperative gene activation by AF4 and DOT1L drives MLL-rearranged leukemia.
Okuda H; Stanojevic B; Kanai A; Kawamura T; Takahashi S; Matsui H; Takaori-Kondo A; Yokoyama A
J Clin Invest; 2017 May; 127(5):1918-1931. PubMed ID: 28394257
[TBL] [Abstract][Full Text] [Related]
6. Small-molecule inhibitor of AF9/ENL-DOT1L/AF4/AFF4 interactions suppresses malignant gene expression and tumor growth.
Wu F; Nie S; Yao Y; Huo T; Li X; Wu X; Zhao J; Lin YL; Zhang Y; Mo Q; Song Y
Theranostics; 2021; 11(17):8172-8184. PubMed ID: 34373735
[TBL] [Abstract][Full Text] [Related]
7. The YEATS domain epigenetic reader proteins ENL and AF9 and their therapeutic value in leukemia.
Hu H; Muntean AG
Exp Hematol; 2023 Aug; 124():15-21. PubMed ID: 37295550
[TBL] [Abstract][Full Text] [Related]
8. Targeting recruitment of disruptor of telomeric silencing 1-like (DOT1L): characterizing the interactions between DOT1L and mixed lineage leukemia (MLL) fusion proteins.
Shen C; Jo SY; Liao C; Hess JL; Nikolovska-Coleska Z
J Biol Chem; 2013 Oct; 288(42):30585-30596. PubMed ID: 23996074
[TBL] [Abstract][Full Text] [Related]
9. An AF9/ENL-targted peptide with therapeutic potential in mixed lineage leukemias.
Barretto NN; Karahalios DS; You D; Hemenway CS
J Exp Ther Oncol; 2014; 10(4):293-300. PubMed ID: 25509985
[TBL] [Abstract][Full Text] [Related]
10. The super elongation complex family of RNA polymerase II elongation factors: gene target specificity and transcriptional output.
Luo Z; Lin C; Guest E; Garrett AS; Mohaghegh N; Swanson S; Marshall S; Florens L; Washburn MP; Shilatifard A
Mol Cell Biol; 2012 Jul; 32(13):2608-17. PubMed ID: 22547686
[TBL] [Abstract][Full Text] [Related]
11. MLL-ENL inhibits polycomb repressive complex 1 to achieve efficient transformation of hematopoietic cells.
Maethner E; Garcia-Cuellar MP; Breitinger C; Takacova S; Divoky V; Hess JL; Slany RK
Cell Rep; 2013 May; 3(5):1553-66. PubMed ID: 23623499
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a Selective Inhibitor for the YEATS Domains of ENL/AF9.
Christott T; Bennett J; Coxon C; Monteiro O; Giroud C; Beke V; Felce SL; Gamble V; Gileadi C; Poda G; Al-Awar R; Farnie G; Fedorov O
SLAS Discov; 2019 Feb; 24(2):133-141. PubMed ID: 30359161
[TBL] [Abstract][Full Text] [Related]
13. The ENL moiety of the childhood leukemia-associated MLL-ENL oncoprotein recruits human Polycomb 3.
García-Cuéllar MP; Zilles O; Schreiner SA; Birke M; Winkler TH; Slany RK
Oncogene; 2001 Jan; 20(4):411-9. PubMed ID: 11313972
[TBL] [Abstract][Full Text] [Related]
14. A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification.
Mueller D; Bach C; Zeisig D; Garcia-Cuellar MP; Monroe S; Sreekumar A; Zhou R; Nesvizhskii A; Chinnaiyan A; Hess JL; Slany RK
Blood; 2007 Dec; 110(13):4445-54. PubMed ID: 17855633
[TBL] [Abstract][Full Text] [Related]
15. Transcription control by the ENL YEATS domain in acute leukaemia.
Erb MA; Scott TG; Li BE; Xie H; Paulk J; Seo HS; Souza A; Roberts JM; Dastjerdi S; Buckley DL; Sanjana NE; Shalem O; Nabet B; Zeid R; Offei-Addo NK; Dhe-Paganon S; Zhang F; Orkin SH; Winter GE; Bradner JE
Nature; 2017 Mar; 543(7644):270-274. PubMed ID: 28241139
[TBL] [Abstract][Full Text] [Related]
16. MLL-AF9 and MLL-ENL alter the dynamic association of transcriptional regulators with genes critical for leukemia.
Monroe SC; Jo SY; Sanders DS; Basrur V; Elenitoba-Johnson KS; Slany RK; Hess JL
Exp Hematol; 2011 Jan; 39(1):77-86.e1-5. PubMed ID: 20854876
[TBL] [Abstract][Full Text] [Related]
17. ENL initiates multivalent phase separation of the super elongation complex (SEC) in controlling rapid transcriptional activation.
Guo C; Che Z; Yue J; Xie P; Hao S; Xie W; Luo Z; Lin C
Sci Adv; 2020 Apr; 6(14):eaay4858. PubMed ID: 32270036
[TBL] [Abstract][Full Text] [Related]
18. A proteolysis-targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growth.
Li X; Yao Y; Wu F; Song Y
J Hematol Oncol; 2022 Apr; 15(1):41. PubMed ID: 35395864
[TBL] [Abstract][Full Text] [Related]
19. The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling.
Bitoun E; Oliver PL; Davies KE
Hum Mol Genet; 2007 Jan; 16(1):92-106. PubMed ID: 17135274
[TBL] [Abstract][Full Text] [Related]
20. Structural studies of intrinsically disordered MLL-fusion protein AF9 in complex with peptidomimetic inhibitors.
Yang Y; Ahmad E; Premkumar V; Liu A; Ashikur Rahman SM; Nikolovska-Coleska Z
Protein Sci; 2024 Jun; 33(6):e5019. PubMed ID: 38747396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]